Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

Fig. 2

Waterfall plots of best change in the target lesion size from baseline of BPI-9016M treated patients. The dashed lines at 20% and -30% indicate the thresholds for PD and PR, respectively. Seven patients (two patients in the 450 mg QD cohort, four patients in the 600 mg QD cohort and one patient in the 400 mg BID cohort) were not evaluable

 QD quaque die, BID bis in die, PD progressive disease, SD stable disease, PR partial response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us